EUVIMEDEUVIMED entdecken
Open Access

Least but not last: Durable C5 silencing for IgA nephropathy

Davide D'Onghia, Annalisa Di Ruscio

Molecular Therapy · 2026-11 · 34 (11) · 6177-6178

DOI: 10.1016/j.ymthe.2026.10.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2026-11. Verfasst von Davide D'Onghia und 1 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School Initiative for RNA Medicine, Harvard Medical School, Boston, MA 02115, USA; Division of Hematology-Oncology, Beth Israel Deaco…. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Harvard Medical School Initiative for RNA Medicine, Harvard Medical School, Boston, MA 02115, USA; Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Cancer R…

Förderung

  • NIDDK NIH HHS

Zitieren

APA

D'Onghia, D., & Di Ruscio, A. (2026). Least but not last: Durable C5 silencing for IgA nephropathy. Molecular Therapy, 34(11), 6177-6178. https://doi.org/10.1016/j.ymthe.2026.10.005

Vancouver

D'Onghia D, Di Ruscio A. Least but not last: Durable C5 silencing for IgA nephropathy. Molecular Therapy. 2026;34(11):6177-6178. doi:10.1016/j.ymthe.2026.10.005

BibTeX
@article{DOnghia2026,
  author = {D'Onghia, Davide and Di Ruscio, Annalisa},
  title = {Least but not last: Durable C5 silencing for IgA nephropathy},
  journal = {Molecular Therapy},
  year = {2026},
  volume = {34},
  number = {11},
  pages = {6177--6178},
  doi = {10.1016/j.ymthe.2026.10.005}
}
Kostenlos starten →